BR112015006738A2 - terapia de combinação usando belinostat e trabectedina - Google Patents

terapia de combinação usando belinostat e trabectedina

Info

Publication number
BR112015006738A2
BR112015006738A2 BR112015006738A BR112015006738A BR112015006738A2 BR 112015006738 A2 BR112015006738 A2 BR 112015006738A2 BR 112015006738 A BR112015006738 A BR 112015006738A BR 112015006738 A BR112015006738 A BR 112015006738A BR 112015006738 A2 BR112015006738 A2 BR 112015006738A2
Authority
BR
Brazil
Prior art keywords
belinostat
trabectedin
combination therapy
combination
solvate
Prior art date
Application number
BR112015006738A
Other languages
English (en)
Inventor
Dumong Erichsen Kamille
Original Assignee
Onxeo Dk Branch Of Onxeo S A France
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Onxeo Dk Branch Of Onxeo S A France filed Critical Onxeo Dk Branch Of Onxeo S A France
Publication of BR112015006738A2 publication Critical patent/BR112015006738A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Dermatology (AREA)

Abstract

resumo patente de invenção: “terapia de combinação usando belinostat e trabectedina”. a presente invenção refere-se às terapias para o tratamento de doenças e distúrbios que são mediados por histona desacetilase (hdac) (por exemplo, câncer, incluindo, por exemplo, câncer ovariano, sarcoma de tecido mole, osteossarcoma, etc.) que empregam uma combinação (por exemplo, uma combinação sinérgica) de (a) belinostat, ou um sal, hidrato, ou solvato do mesmo, e (b) trabectedina, ou um sal, hidrato, ou solvato da mesma.
BR112015006738A 2012-09-28 2013-09-26 terapia de combinação usando belinostat e trabectedina BR112015006738A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261707063P 2012-09-28 2012-09-28
GBGB1217439.7A GB201217439D0 (en) 2012-09-28 2012-09-28 Combination therapy
PCT/IB2013/058891 WO2014049549A1 (en) 2012-09-28 2013-09-26 Combination therapy using belinostat and trabectedin

Publications (1)

Publication Number Publication Date
BR112015006738A2 true BR112015006738A2 (pt) 2017-07-04

Family

ID=47225413

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015006738A BR112015006738A2 (pt) 2012-09-28 2013-09-26 terapia de combinação usando belinostat e trabectedina

Country Status (10)

Country Link
US (1) US20150231134A1 (pt)
EP (1) EP2900271A1 (pt)
JP (1) JP2015531367A (pt)
KR (1) KR20150063070A (pt)
BR (1) BR112015006738A2 (pt)
CA (1) CA2884923A1 (pt)
GB (1) GB201217439D0 (pt)
MX (1) MX2015003800A (pt)
RU (1) RU2015109086A (pt)
WO (1) WO2014049549A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9421264B2 (en) 2014-03-28 2016-08-23 Duke University Method of treating cancer using selective estrogen receptor modulators
EP3834824A1 (en) 2014-03-28 2021-06-16 Duke University Method of treating cancer using selective estrogen receptor modulators
IL307981A (en) 2015-04-29 2023-12-01 Radius Pharmaceuticals Inc Cancer treatment methods
MX2018009088A (es) * 2016-02-04 2018-09-03 Jiangsu Hengrui Medicine Co Composicion farmaceutica inyectable que incluye trabectedina para uso gastrointestinal externo y metodo para la fabricacion de la misma.
PL3518911T3 (pl) * 2016-09-27 2022-02-07 Radius Pharmaceuticals, Inc. Rad1901 do zastosowania w leczeniu nowotworu jajnika
JP7481115B2 (ja) 2017-01-05 2024-05-10 ラジウス ファーマシューティカルズ，インコーポレイテッド Ｒａｄ１９０１－２ｈｃｌの多形性形態
WO2019002614A1 (en) * 2017-06-30 2019-01-03 Onxeo NEW ORAL FORMULATIONS OF BELINOSTAT
CN110996913A (zh) * 2017-06-30 2020-04-10 欧恩科斯欧公司 新的贝利司他口服制剂
SG11202013177WA (en) 2018-07-04 2021-01-28 Radius Pharmaceuticals Inc Polymorphic forms of rad 1901-2hcl
AU2021256746A1 (en) * 2020-04-15 2022-11-03 Ever Valinject Gmbh Composition comprising trabectedin and an amino acid

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2428160C (en) * 2000-11-06 2009-10-13 Pharma Mar, S.A. Compositions for antitumor treatment containing ecteinascidin 743
CA2462502A1 (en) * 2001-10-19 2003-05-15 Pharma Mar, S.A. Improved use of antitumoral compound in cancer therapy
EP2500063A1 (en) * 2005-02-03 2012-09-19 TopoTarget UK Limited Combination therapy using HDAC inhibitors and melphalan for treating cancer
EP1957056A2 (en) * 2005-11-10 2008-08-20 TopoTarget UK Limited Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent

Also Published As

Publication number Publication date
EP2900271A1 (en) 2015-08-05
WO2014049549A1 (en) 2014-04-03
CA2884923A1 (en) 2014-04-03
MX2015003800A (es) 2015-10-05
US20150231134A1 (en) 2015-08-20
GB201217439D0 (en) 2012-11-14
KR20150063070A (ko) 2015-06-08
RU2015109086A (ru) 2016-11-20
JP2015531367A (ja) 2015-11-02

Similar Documents

Publication Publication Date Title
BR112015006738A2 (pt) terapia de combinação usando belinostat e trabectedina
GEP20217316B (en) Aromatic sulfonamide derivatives
BR112018000906A2 (pt) ?composto, medicamento, métodos de inibição da histona desacetilase em um mamífero, e para a profilaxia ou o tratamento de doenças, e, uso de um composto?
BR112017011972A2 (pt) derivados de azabicicloctano como agonistas de fxr para uso no tratamento de doenças hepáticas e gastrintestinais
BR112017007072A2 (pt) compostos de triazolopiridina e métodos para o tratamento de fibrose cística
BR112017002332A2 (pt) terapia de combinação para o tratamento de um paramixovírus
BR112014001600A2 (pt) composto inibidor do trajeto de sinalização notch
BR112017027951A2 (pt) composto inibitório de brk
BR112014029868A2 (pt) compostos, e, composição farmacêutica
BR112015023349A2 (pt) composto, composição farmacêutica, e, método de tratamento de uma doença, condição de saúde ou distúrbio
EA201591727A1 (ru) Соединения биариламида в качестве ингибиторов киназы
WO2015117010A3 (en) Bag3 as a target for therapy of heart failure
BR112017003571A2 (pt) terapia combinada
BR112016005271A2 (pt) Moduladores de canais de sódio para o tratamento da dor e do diabetes
BR112016027041A8 (pt) combinações farmacêuticas para tratamento do câncer
BR112015010109A2 (pt) derivados de indol-5-ol substituídos e suas aplicações terapêuticas
EA201500365A1 (ru) Комбинация регорафениба и ацетилсалициловой кислоты для лечения рака
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
EA201790700A1 (ru) Моно- или дизамещенные индолы в качестве ингибиторов репликации вирусов денге
UY36080A (es) Compuestos inhibidores de metaloenzima como fungicidas.
BR112017010440A2 (pt) administração sublingual de riluzol
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112018011700A2 (pt) ?moduladores de canais de kv3 para tratar dor?
BR112014019399A2 (pt) métodos de tratamento da fibrose
BR112015018360A2 (pt) terapia de combinação para o tratamento de pneumonia nosocomial

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]